Open Access

Drug distribution and clinical safety in treating cystic craniopharyngiomas using intracavitary radiotherapy with phosphorus-32 colloid

  • Authors:
    • Hongbo Chang
    • Jianning Zhang
    • Weidong Cao
    • Yaming Wang
    • Hulin Zhao
    • Rui Liu
    • Shengli Guo
  • View Affiliations

  • Published online on: February 7, 2018     https://doi.org/10.3892/ol.2018.7981
  • Pages: 4997-5003
  • Copyright: © Chang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The present study evaluated drug distribution and clinical safety in treating patients with cystic craniopharyngioma (CP) with intracavitary radiotherapy using phosphorus‑32 (32P) colloid. In total, 40 patients who were recently diagnosed with primary or recurrent cystic CP were enrolled into the study. Patients underwent stereotactic intracavitary therapy and were administered 32P colloid and iopamidol‑300 (1:1 dilution). Head computed tomography (CT) scans were performed 2 h after surgery in order to assess drug distribution and leakage. Results obtained from the ophthalmic examination (visual acuity, visual field and fundus), enhanced head magnetic resonance imaging and/or CT scans, blood analysis, coagulation tests, electrolyte tests, pituitary hormone level analysis, and hepatic and renal function tests were compared between the 0.5, 1, 1.5 and 2 mCi groups. The 32P colloid per minute radioactive count was quantitatively measured in urine and blood samples using a CAPRAC well‑type NaI γ counter at 1, 3 and 7 days post‑surgery. In total, 6, 2 and 1 case(s) from the 2, 1.5 and 1 mCi groups, respectively, demonstrated heterogeneous drug distribution and intracavitary cerebrospinal fluid leakage. Furthermore, out of 24 patients, no significant differences were identified in blood analysis, blood biochemical measurements and pituitary hormone levels prior to and 7 days after surgery. Blood 32P deposition returned to normal levels within 3 days after surgery, whereas urine deposition returned to normal within 7 days after surgery. Methods utilized in the present study were advantageous in terms of convenience, speed and low cost, therefore, these techniques are suitable for continuous monitoring of patient 32P colloid deposition.

References

1 

Liubinas SV, Munshey AS and Kaye AH: Management of recurrent craniopharyngioma. J Clin Neurosci. 18:451–457. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Taasan V, Shapiro B, Taren JA, Beierwaltes WH, McKeever P, Wahl RL, Carey JE, Petry N and Mallette S: Phosphorus-32 therapy of cystic Grade IV astrocytomas: Technique and preliminary application. J Nucl Med. 26:1335–1338. 1985.PubMed/NCBI

3 

Hasegawa T, Kondziolka D, Hadjipanayis CG and Lunsford LD: Management of cystic craniopharyngiomas with phosphorus-32 intracavitary irradiation. Neurosurgery. 54:813–820. 2004. View Article : Google Scholar : PubMed/NCBI

4 

Kickingereder P, Maarouf M, El Majdoub F, Fuetsch M, Lehrke R, Wirths J, Luyken K, Schomaecker K, Treuer H, Voges J and Sturm V: Intracavitary brachytherapy using stereotactically applied phosphorus-32 colloid for treatment of cystic craniopharyngiomas in 53 patients. J Neurooncol. 109:365–374. 2012. View Article : Google Scholar : PubMed/NCBI

5 

Tian Z, Liu Z and Wang Y: Stereotactic intratumoral irradiation of huge craniopharyngioma. Zhonghua Zhong Liu Za Zhi. 18:234–236. 1996.(In Chinese). PubMed/NCBI

6 

Yu X, Zhang JN, Liu R, Wang YM, Sun JZ, Qi SB, DU YN, Wang HW, Zhao HL and Liu ZH: Mixed craniopharyngioma: Long-term results after gamma knife combined with stereotactic brachytherapy. Zhonghua Wai Ke Za Zhi. 51:631–635. 2013.(In Chinese). PubMed/NCBI

7 

Trippel M and Nikkhah G: Stereotactic neurosurgical treatment options for craniopharyngioma. Front Endocrinol (Lausanne). 3:632012.PubMed/NCBI

8 

Denis-Bacelar AM, Romanchikova M, Chittenden S, Saran FH, Mandeville H, Du Y and Flux GD: Patient-specific dosimetry for intracavitary 32P-chromic phosphate colloid therapy of cystic brain tumours. Eur J Nucl Med Mol Imaging. 40:1532–1541. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Liu L, Teng G, Zhang D, Song J, He S, Guo J and Fang W: Toxicology of intrahepatic arterial administration of interventional phosphorus-32 glass microspheres to domestic pigs. Chin Med J (Engl). 112:632–636. 1999.PubMed/NCBI

10 

Gaca P, Warwick PE and Croudace IW: Liquid scintillation counters calibration stability over long timescales. J Radioanal Nucl Chem. 314:753–760. 2017. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chang, H., Zhang, J., Cao, W., Wang, Y., Zhao, H., Liu, R., & Guo, S. (2018). Drug distribution and clinical safety in treating cystic craniopharyngiomas using intracavitary radiotherapy with phosphorus-32 colloid. Oncology Letters, 15, 4997-5003. https://doi.org/10.3892/ol.2018.7981
MLA
Chang, H., Zhang, J., Cao, W., Wang, Y., Zhao, H., Liu, R., Guo, S."Drug distribution and clinical safety in treating cystic craniopharyngiomas using intracavitary radiotherapy with phosphorus-32 colloid". Oncology Letters 15.4 (2018): 4997-5003.
Chicago
Chang, H., Zhang, J., Cao, W., Wang, Y., Zhao, H., Liu, R., Guo, S."Drug distribution and clinical safety in treating cystic craniopharyngiomas using intracavitary radiotherapy with phosphorus-32 colloid". Oncology Letters 15, no. 4 (2018): 4997-5003. https://doi.org/10.3892/ol.2018.7981